Literature DB >> 33523635

Receptor-Ligand Kinetics Influence the Mechanism of Action of Covalently Linked TLR Ligands.

Flora W Kimani1, Jainu Ajit1, Alexander Galluppi1, Saikat Manna1, William J Howitz2, Sophia Tang1, Aaron P Esser-Kahn1.   

Abstract

We report a mechanistic study comparing the immune activation of conjugated Toll-like receptor (TLR) agonists and their unlinked mixtures. Herein, we synthesized a set of six linked dual agonists with different ligands, molecular structures, receptor locations, and biophysical characteristics. With these dimers, we ran a series of in vitro cell-based assays, comparing initial and overall NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation, cytokine expression profiles, as well as time-resolved TNF-α (Tumor Necrosis Factor alpha) expression. We show that initial activation kinetics, ligand specificity, and the dose of the agonist influence the activity of these linked TLR systems. These results can help improve vaccine design by showing how linked TLR agonists can improve their potency with the appropriate selection of key criteria.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33523635      PMCID: PMC8936418          DOI: 10.1021/acschembio.0c00924

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  30 in total

1.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells.

Authors:  Giorgio Napolitani; Andrea Rinaldi; Francesco Bertoni; Federica Sallusto; Antonio Lanzavecchia
Journal:  Nat Immunol       Date:  2005-07-03       Impact factor: 25.606

2.  Toll-like receptors: the interface between innate and adaptive immunity.

Authors:  Peter G Tipping
Journal:  J Am Soc Nephrol       Date:  2006-06-14       Impact factor: 10.121

Review 3.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

4.  Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.

Authors:  Nikunj M Shukla; Subbalakshmi S Malladi; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

5.  Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2.

Authors:  A O Aliprantis; R B Yang; M R Mark; S Suggett; B Devaux; J D Radolf; G R Klimpel; P Godowski; A Zychlinsky
Journal:  Science       Date:  1999-07-30       Impact factor: 47.728

6.  Cellular Decision Making by Non-Integrative Processing of TLR Inputs.

Authors:  Ryan A Kellogg; Chengzhe Tian; Martin Etzrodt; Savaş Tay
Journal:  Cell Rep       Date:  2017-04-04       Impact factor: 9.423

Review 7.  Translational mini-review series on Toll-like receptors: networks regulated by Toll-like receptors mediate innate and adaptive immunity.

Authors:  L C Parker; L R Prince; I Sabroe
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

8.  Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands.

Authors:  Michael Chan; Tomoko Hayashi; Richard D Mathewson; Afshin Nour; Yuki Hayashi; Shiyin Yao; Rommel I Tawatao; Brian Crain; Igor F Tsigelny; Valentina L Kouznetsova; Karen Messer; Minya Pu; Maripat Corr; Dennis A Carson; Howard B Cottam
Journal:  J Med Chem       Date:  2013-05-24       Impact factor: 7.446

9.  A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.

Authors:  Mark T Orr; Elyse A Beebe; Thomas E Hudson; James J Moon; Christopher B Fox; Steven G Reed; Rhea N Coler
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

10.  Modulation of Innate Immune Responses via Covalently Linked TLR Agonists.

Authors:  Janine K Tom; Emmanuel Y Dotsey; Hollie Y Wong; Lalisa Stutts; Troy Moore; D Huw Davies; Philip L Felgner; Aaron P Esser-Kahn
Journal:  ACS Cent Sci       Date:  2015-10-28       Impact factor: 14.553

View more
  1 in total

Review 1.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.